Finnish Institute for Health and Welfare, later referred to as THL, request your tender for Antidotes and poisoning medical products (part 2) to the rescEU project. The Scope of procurement is described in more detail in Annex 1. The procurement is divided in nine (9) lots. Tender may be submitted for one or several lots. - LOT 1: Naloxone 1 mg/ml (2 ml per pre-filled syringe, ATC V03AB15) - LOT 2: Naloxone 0,4 mg/ml (1 ml per vial/ampoule, ATC V03AB15) - LOT 3: Sodiumthiosulfate 25 % (100 ml per vial/ampule, ATC V03AB06) - LOT 4: Physostigmine 2 mg/5 ml (5 ml per vial/ampoule, ATC V03AB19) - LOT 5: Ethanol 95 – 96 % / 20 ml (20 ml per vial/ampoule, ATC V03AB16) - LOT 6: Silibinin (350 mg powder for i.v. / vial, ATC V03AX) - LOT 7: Atropine sulphate 10 mg/ml (10 ml per vial/ampoule, ATC A03BA01) - LOT 8: Pegfilgrastim 6 mg/0,6 ml (0,6 ml per vial/ampoule, ATC L03AA13) - LOT 9: Naloxone / single dose container (no further device assembly is required, ATC V03AB15) All products are for CBRN poisoning treatment or CBRN antidotes. The minimum requirements for the articles is described in Annex 1.1. The contract will be awarded to one Supplier for each lot based on a comparison of tenders. Tender that is economically the most advantageous will win the competition. The contract period shall enter into force once the contract has been signed by contracting parties and expires when all contractual duties of the contract have been performed. Estimated quantity for the product in described in Annex 6 (restricted to security classification level IV, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Supplier is not obliged to deliver the Articles under the Option. Please note that all times given in the Call for Tenders refer to local time in Finland. Call for Tenders, Annexes: Annex 1 Scope of the procurement Annex 1.1 Minimum requirements Annex 2 Contract Annex 3 Security annex Annex 4 Description of the Handi service Annex 5 JYSE 2014 SUPPLIES (updated version of April 2022) Annex 6 Estimated quantity (restricted, TL IV) Annex 7 Confidentiality commitment Please note that the numbering of the annexes differs between the Contract and the Call for Tenders.
Määräaika
Tarjousten vastaanottamisen määräaika oli 2024-02-26.
Hankinta julkaistiin 2024-01-22.
hankintailmoitus (2024-01-22) Kohde Hankinnan laajuus
Otsikko: Antidotes and poisoning medical products, part 2 / 2024-2025
Reference number: THL/236/2.02.06/2024
Lyhyt kuvaus:
“Finnish Institute for Health and Welfare, later referred to as THL, request your tender for Antidotes and poisoning medical products (part 2) to the rescEU...”
Lyhyt kuvaus
Finnish Institute for Health and Welfare, later referred to as THL, request your tender for Antidotes and poisoning medical products (part 2) to the rescEU project. The Scope of procurement is described in more detail in Annex 1. The procurement is divided in nine (9) lots. Tender may be submitted for one or several lots. - LOT 1: Naloxone 1 mg/ml (2 ml per pre-filled syringe, ATC V03AB15) - LOT 2: Naloxone 0,4 mg/ml (1 ml per vial/ampoule, ATC V03AB15) - LOT 3: Sodiumthiosulfate 25 % (100 ml per vial/ampule, ATC V03AB06) - LOT 4: Physostigmine 2 mg/5 ml (5 ml per vial/ampoule, ATC V03AB19) - LOT 5: Ethanol 95 – 96 % / 20 ml (20 ml per vial/ampoule, ATC V03AB16) - LOT 6: Silibinin (350 mg powder for i.v. / vial, ATC V03AX) - LOT 7: Atropine sulphate 10 mg/ml (10 ml per vial/ampoule, ATC A03BA01) - LOT 8: Pegfilgrastim 6 mg/0,6 ml (0,6 ml per vial/ampoule, ATC L03AA13) - LOT 9: Naloxone / single dose container (no further device assembly is required, ATC V03AB15) All products are for CBRN poisoning treatment or CBRN antidotes. The minimum requirements for the articles is described in Annex 1.1. The contract will be awarded to one Supplier for each lot based on a comparison of tenders. Tender that is economically the most advantageous will win the competition. The contract period shall enter into force once the contract has been signed by contracting parties and expires when all contractual duties of the contract have been performed. Estimated quantity for the product in described in Annex 6 (restricted to security classification level IV, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Supplier is not obliged to deliver the Articles under the Option. Please note that all times given in the Call for Tenders refer to local time in Finland. Call for Tenders, Annexes: Annex 1 Scope of the procurement Annex 1.1 Minimum requirements Annex 2 Contract Annex 3 Security annex Annex 4 Description of the Handi service Annex 5 JYSE 2014 SUPPLIES (updated version of April 2022) Annex 6 Estimated quantity (restricted, TL IV) Annex 7 Confidentiality commitment Please note that the numbering of the annexes differs between the Contract and the Call for Tenders.
Näytä lisää
Sopimustyyppi: supplies
Tuotteet/palvelut: Muut lääkkeet📦 Tietoa eristä
Tämä sopimus on jaettu osiin ✅
Yhdelle tarjoajalle myönnettävien erien enimmäismäärä: 9
Tarjouksia voidaan jättää enintään yhtä erää varten: 9
1️⃣
Hankinnan kuvaus:
“The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Naloxone 1 mg/ml (2 ml per pre-filled...”
Hankinnan kuvaus
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Naloxone 1 mg/ml (2 ml per pre-filled syringe, ATC V03AB15) - Parenteral products (intramuscular administration) for CBRN poisoning treatment or CBRN antidotes - Active pharmaceutical ingredient: Naloxone - Strength: 1 mg/ml - Pharmaceutical form: pre-filled syringe The minimum requirements of the article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Näytä lisää
Lisätuotteet/palvelut: Farmaseuttiset tuotteet📦
Kesto: 17 (MONTH)
Jäljempänä oleva aikataulu on ilmaistu kuukausina.
Tietoa vaihtoehdoista
Vaihtoehdot ✅
Vaihtoehtojen kuvaus:
“In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred...”
Vaihtoehtojen kuvaus
In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
Näytä lisää Myöntämisperusteet
Hinta ✅
Laatukriteeri (nimi): Quality 1: Registered shelf life of the product
Laatukriteeri (nimi): Quality 2: Delivery time to the customer’s warehouse
Laatukriteeri (nimi): Quality 3: Language of packaging and product information leaflet
Laatukriteeri (nimi): Quality 4: Transportation temperature and excursions
Laatukriteeri (nimi): Quality 5: EMA centralized EU Marketing Authorisation for the product
Otsikko
Erän tunnistenumero: LOT-0001
2️⃣
Hankinnan kuvaus:
“The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Naloxone 0,4 mg/ml (1 ml per vial/ampoule,...”
Hankinnan kuvaus
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Naloxone 0,4 mg/ml (1 ml per vial/ampoule, ATC V03AB15) - Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes - Active pharmaceutical ingredient: Naloxone - Strength: 0,4 mg/ml - Pharmaceutical form: vial/ampoule The minimum requirements of the article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
3️⃣
Hankinnan kuvaus:
“The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Sodiumthiosulfate 25 % (100 ml per...”
Hankinnan kuvaus
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Sodiumthiosulfate 25 % (100 ml per vial/ampule, ATC V03AB06) - Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes - Active pharmaceutical ingredient: Sodiumthiosulfate - Strength: 25 % / 100 ml - Pharmaceutical form: vial/ampule The minimum requirements of the article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
4️⃣
Hankinnan kuvaus:
“The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Physostigmine 2 mg / 5 ml (5 ml per...”
Hankinnan kuvaus
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Physostigmine 2 mg / 5 ml (5 ml per vial/ampoule, ATC V03AB19) - Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes - Active pharmaceutical ingredient: Physostigmine - Strength: 2 mg / 5 ml - Pharmaceutical form: vial/ampoule The minimum requirements of the article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
5️⃣
Hankinnan kuvaus:
“The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Ethanol 95 – 96 % / 20 ml (20 ml per...”
Hankinnan kuvaus
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Ethanol 95 – 96 % / 20 ml (20 ml per vial/ampoule, ATC V03AB16) - Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes - Active pharmaceutical ingredient: Ethanol - Strength: 95 – 96 % / 20 ml - Pharmaceutical form: vial/ampoule The minimum requirements of the article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
6️⃣
Hankinnan kuvaus:
“The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Silibinin (350 mg powder for i.v. / vial,...”
Hankinnan kuvaus
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Silibinin (350 mg powder for i.v. / vial, ATC V03AX) - Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes - Active pharmaceutical ingredient: Silibinin - Pharmaceutical form: powder for i.v. / vial The minimum requirements of the article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
7️⃣
Hankinnan kuvaus:
“The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Atropine sulphate 10 mg/ml (10 ml per...”
Hankinnan kuvaus
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Atropine sulphate 10 mg/ml (10 ml per vial/ampoule, ATC A03BA01) - Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes - Active pharmaceutical ingredient: Atropine sulphate - Strength: 10 mg/ml - Pharmaceutical form: vial/ampoule The minimum requirements of the article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
8️⃣
Hankinnan kuvaus:
“The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Pegfilgrastim 6 mg / 0,6 ml (0,6 ml per...”
Hankinnan kuvaus
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Pegfilgrastim 6 mg / 0,6 ml (0,6 ml per vial/ampoule, ATC L03AA13) - Parenteral products (sub-cutaneous) for CBRN poisoning treatment or CBRN antidotes - Active pharmaceutical ingredient: Pegfilgrastim - Strength: 6 mg / 0,6 ml - Pharmaceutical form: vial/ampoule The minimum requirements of the article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
9️⃣
Hankinnan kuvaus:
“The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Naloxone / single dose container (no...”
Hankinnan kuvaus
The subject of the procurement is article in accordance with the following requirements: - The subject of tender: Naloxone / single dose container (no further device assembly is required, ATC V03AB15) - Solutions for nasal use for CBRN poisoning treatment or CBRN antidotes - Active pharmaceutical ingredient: Naloxone - Pharmaceutical form: single dose container (no further device assembly is required) The minimum requirements of the article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Menettely Toimenpiteen tyyppi
Avoin menettely ✅ Hallinnolliset tiedot
Tarjousten tai osallistumishakemusten vastaanottamisen määräaika: 2024-02-26 12:00:00 📅
Tarjousten avaamista koskevat ehdot: 2024-02-26 12:30:00 📅
Kielet, joilla tarjoukset tai osallistumishakemukset voidaan jättää: englanti 🗣️
Vähimmäisaika, jonka kuluessa tarjoajan on pidettävä tarjous voimassa: 6
Oikeudelliset, taloudelliset, rahoitukselliset ja tekniset tiedot Taloudellinen ja rahoituksellinen asema
Luettelo ja lyhyt kuvaus valintaperusteista:
“Yearly turnover: Its (“general”) yearly turnover is as follows: Year 2022: 1000000,00 EUR Year 2021: 1000000,00 EUR” Osallistumisehdot
Luettelo ja lyhyt kuvaus olosuhteista:
“Enrolment in a relevant professional register: It is enrolled in the relevant professional registers kept in the Member State of its establishment.”
Luettelo ja lyhyt kuvaus olosuhteista:
“Enrolment in a trade register: It is enrolled in the relevant trade registers kept in the Member State of its establishment.” Sopimukseen liittyvät ehdot
Sopimuksen täytäntöönpanoehdot:
“For further details please see the documents of the Call for Tenders.”
“The availability for the Annex 6 is restricted to security classification level IV, TL IV. THL will send the restricted Annex 6 to a representative of the...”
The availability for the Annex 6 is restricted to security classification level IV, TL IV. THL will send the restricted Annex 6 to a representative of the tenderer via encrypted email after THL has received the signed confidentiality commitment (Annex 7). Confidentiality commitment shall be signed by a legal representative of tenderer. Confidentiality commitment shall be sent to the email address kirjaamo@thl.fi with the subject line "CONFIDENTIALITY COMMITMENT - THL/236/2.02.06/2024 / Antidotes and poisoning medical products, part 2". The message shall contain name of the tenderer and email address to which the restricted Annex 6 is to be sent.
Näytä lisää Arvostelurunko
Nimi: Markkinaoikeus
Kansallinen rekisterinumero: 3006157-6
Postiosoite: Radanrakentajantie 5
Postinumero: 00520
Postitoimipaikka: Helsinki
Alue: Helsinki-Uusimaa🏙️
Maa: Suomi 🇫🇮
Sähköposti: markkinaoikeus@oikeus.fi📧
Puhelin: +358 295643300📞
URL: http://www.oikeus.fi/markkinaoikeus🌏 Tietoa sähköisistä työnkuluista
Sähköinen laskutus hyväksytään
Sähköistä tilaamista käytetään
Sähköistä maksua käytetään
Lähde: OJS 2024/S 017-048903 (2024-01-22)
hankintailmoitus (2024-02-08) Kohde Hankinnan laajuus
Lyhyt kuvaus:
“Finnish Institute for Health and Welfare, later referred to as THL, request your tender for Antidotes and poisoning medical products (part 2) to the rescEU...”
Lyhyt kuvaus
Finnish Institute for Health and Welfare, later referred to as THL, request your tender for Antidotes and poisoning medical products (part 2) to the rescEU project. The Scope of procurement is described in more detail in Annex 1.
The procurement is divided in nine (9) lots. Tender may be submitted for one or several lots.
- LOT 1: Naloxone 1 mg/ml (2 ml per pre-filled syringe, ATC V03AB15)
- LOT 2: Naloxone 0,4 mg/ml (1 ml per vial/ampoule, ATC V03AB15)
- LOT 3: Sodiumthiosulfate 25 % (100 ml per vial/ampule, ATC V03AB06)
- LOT 4: Physostigmine 2 mg/5 ml (5 ml per vial/ampoule, ATC V03AB19)
- LOT 5: Ethanol 95 – 96 % / 20 ml (20 ml per vial/ampoule, ATC V03AB16)
- LOT 6: Silibinin (350 mg powder for i.v. / vial, ATC V03AX)
- LOT 7: Atropine sulphate 10 mg/ml (10 ml per vial/ampoule, ATC A03BA01)
- LOT 8: Pegfilgrastim 6 mg/0,6 ml (0,6 ml per vial/ampoule/prefilled syringe, ATC L03AA13)
- LOT 9: Naloxone / single dose container (no further device assembly is required, ATC V03AB15)
All products are for CBRN poisoning treatment or CBRN antidotes.
The minimum requirements for the articles is described in Annex 1.1.
The contract will be awarded to one Supplier for each lot based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
The contract period shall enter into force once the contract has been signed by contracting parties and expires when all contractual duties of the contract have been performed.
Estimated quantity for the product in described in Annex 6 (restricted to security classification level IV, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Supplier is not obliged to deliver the Articles under the Option.
Please note that all times given in the Call for Tenders refer to local time in Finland.
Call for Tenders, Annexes:
Annex 1 Scope of the procurement
Annex 1.1 Minimum requirements
Annex 2 Contract
Annex 3 Security annex
Annex 4 Description of the Handi service
Annex 5 JYSE 2014 SUPPLIES (updated version of April 2022)
Annex 6 Estimated quantity (restricted, TL IV)
Annex 7 Confidentiality commitment
Please note that the numbering of the annexes differs between the Contract and the Call for Tenders.
Näytä lisää Kuvaus
Hankinnan kuvaus:
“The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Naloxone 1 mg/ml (2 ml per pre-filled...”
Hankinnan kuvaus
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Naloxone 1 mg/ml (2 ml per pre-filled syringe, ATC V03AB15)
- Parenteral products (intramuscular administration) for CBRN poisoning treatment or CBRN antidotes
- Active pharmaceutical ingredient: Naloxone
- Strength: 1 mg/ml
- Pharmaceutical form: pre-filled syringe
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Näytä lisää
Hankinnan kuvaus:
“The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Naloxone 0,4 mg/ml (1 ml per...”
Hankinnan kuvaus
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Naloxone 0,4 mg/ml (1 ml per vial/ampoule, ATC V03AB15)
- Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes
- Active pharmaceutical ingredient: Naloxone
- Strength: 0,4 mg/ml
- Pharmaceutical form: vial/ampoule
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Näytä lisää
Hankinnan kuvaus:
“The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Sodiumthiosulfate 25 % (100 ml per...”
Hankinnan kuvaus
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Sodiumthiosulfate 25 % (100 ml per vial/ampule, ATC V03AB06)
- Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes
- Active pharmaceutical ingredient: Sodiumthiosulfate
- Strength: 25 % / 100 ml
- Pharmaceutical form: vial/ampule
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Näytä lisää
Hankinnan kuvaus:
“The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Physostigmine 2 mg / 5 ml (5 ml per...”
Hankinnan kuvaus
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Physostigmine 2 mg / 5 ml (5 ml per vial/ampoule, ATC V03AB19)
- Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes
- Active pharmaceutical ingredient: Physostigmine
- Strength: 2 mg / 5 ml
- Pharmaceutical form: vial/ampoule
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Näytä lisää
Hankinnan kuvaus:
“The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Ethanol 95 – 96 % / 20 ml (20 ml per...”
Hankinnan kuvaus
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Ethanol 95 – 96 % / 20 ml (20 ml per vial/ampoule, ATC V03AB16)
- Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes
- Active pharmaceutical ingredient: Ethanol
- Strength: 95 – 96 % / 20 ml
- Pharmaceutical form: vial/ampoule
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Näytä lisää
Hankinnan kuvaus:
“The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Silibinin (350 mg powder for i.v. / vial,...”
Hankinnan kuvaus
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Silibinin (350 mg powder for i.v. / vial, ATC V03AX)
- Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes
- Active pharmaceutical ingredient: Silibinin
- Pharmaceutical form: powder for i.v. / vial
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Näytä lisää
Hankinnan kuvaus:
“The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Atropine sulphate 10 mg/ml (10 ml per...”
Hankinnan kuvaus
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Atropine sulphate 10 mg/ml (10 ml per vial/ampoule, ATC A03BA01)
- Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes
- Active pharmaceutical ingredient: Atropine sulphate
- Strength: 10 mg/ml
- Pharmaceutical form: vial/ampoule
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Näytä lisää
Hankinnan kuvaus:
“The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Pegfilgrastim 6 mg / 0,6 ml (0,6 ml per...”
Hankinnan kuvaus
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Pegfilgrastim 6 mg / 0,6 ml (0,6 ml per vial/ampoule/prefilled syringe, ATC L03AA13)
- Parenteral products (sub-cutaneous) for CBRN poisoning treatment or CBRN antidotes
- Active pharmaceutical ingredient: Pegfilgrastim
- Strength: 6 mg / 0,6 ml
- Pharmaceutical form: vial/ampoule/prefilled syringe
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Näytä lisää
Hankinnan kuvaus:
“The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Naloxone / single dose container (no...”
Hankinnan kuvaus
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Naloxone / single dose container (no further device assembly is required, ATC V03AB15)
- Solutions for nasal use for CBRN poisoning treatment or CBRN antidotes
- Active pharmaceutical ingredient: Naloxone
- Pharmaceutical form: single dose container (no further device assembly is required)
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
“In the case of "LOT 8: Pegfilgrastim 6 mg/0,6 ml (0,6 ml per vial/ampoule, ATC L03AA13)", the pharmaceutical form "prefilled syringe" has not been indicated...”
In the case of "LOT 8: Pegfilgrastim 6 mg/0,6 ml (0,6 ml per vial/ampoule, ATC L03AA13)", the pharmaceutical form "prefilled syringe" has not been indicated in the original Call for tenders. Prefilled syringe is also an acceptable pharmaceutical form for LOT 8, which is why it has been added to the Call for tenders.
The procurement documents have been amended to reflect this change.
The deadline for submitting additional questions has been extended until 14/02/2024, 12:00 (GMT+2).
Näytä lisää
Lähde: OJS 2024/S 029-086075 (2024-02-08)